PBF-1650 / Palobiofarma, Ligand - LARVOL DELTA

Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers. (clinicaltrials.gov) - P1; N=32; Completed; Sponsor: Palobiofarma SL; Recruiting ➔ Completed

Clinical • Trial completion • Dermatology • Dermatopathology • Immunology • Psoriasis